MDxHealth SA ADR (MDXH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MDxHealth SA ADR (MDXH) has a cash flow conversion efficiency ratio of 0.192x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.85 Million) by net assets ($-30.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MDxHealth SA ADR (MDXH) total market value for the company's overall valuation and market capitalisation.
MDxHealth SA ADR - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how MDxHealth SA ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MDxHealth SA ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MDxHealth SA ADR ranked by their cash flow conversion efficiency. Explore MDxHealth SA ADR cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Paramount Gold Nevada Corp
NYSE MKT:PZG
|
0.070x |
|
Jindal Poly Investment and Finance Company Limited
NSE:JPOLYINVST
|
0.004x |
|
Kino Indonesia Tbk PT
JK:KINO
|
0.132x |
|
Hiap Teck Venture Bhd
KLSE:5072
|
-0.022x |
|
Cellectis
PA:ALCLS
|
-0.348x |
|
Reward Wool Industry Corp
TW:1423
|
0.004x |
|
Jiin Ming Industry Co Ltd
TWO:3230
|
0.026x |
|
Orion Energy Systems Inc
NASDAQ:OESX
|
0.072x |
Annual Cash Flow Conversion Efficiency for MDxHealth SA ADR (2004–2025)
The table below shows the annual cash flow conversion efficiency of MDxHealth SA ADR from 2004 to 2025. View MDxHealth SA ADR stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-12.09 Million | $-10.42 Million | 0.861x | +168.99% |
| 2024-12-31 | $14.84 Million | $-18.53 Million | -1.249x | +58.14% |
| 2023-12-31 | $7.21 Million | $-21.50 Million | -2.982x | +18.57% |
| 2022-12-31 | $9.31 Million | $-34.12 Million | -3.663x | -661.83% |
| 2021-12-31 | $46.90 Million | $-22.55 Million | -0.481x | +86.11% |
| 2020-12-31 | $5.85 Million | $-20.24 Million | -3.461x | -206.28% |
| 2019-12-31 | $19.72 Million | $-22.29 Million | -1.130x | -106.34% |
| 2018-12-31 | $52.12 Million | $-28.54 Million | -0.548x | -127.37% |
| 2017-12-31 | $43.55 Million | $-10.49 Million | -0.241x | +23.40% |
| 2016-12-31 | $52.74 Million | $-16.59 Million | -0.314x | +3.30% |
| 2015-12-31 | $44.26 Million | $-14.39 Million | -0.325x | +58.24% |
| 2014-12-31 | $23.78 Million | $-18.51 Million | -0.779x | -35.45% |
| 2013-12-31 | $24.54 Million | $-14.11 Million | -0.575x | +18.11% |
| 2012-12-31 | $16.02 Million | $-11.25 Million | -0.702x | -21.14% |
| 2011-12-31 | $14.67 Million | $-8.50 Million | -0.580x | +23.56% |
| 2010-12-31 | $14.26 Million | $-10.81 Million | -0.758x | -11.36% |
| 2009-12-31 | $26.94 Million | $-18.34 Million | -0.681x | -138.61% |
| 2008-12-31 | $45.44 Million | $-12.96 Million | -0.285x | +13.86% |
| 2007-12-31 | $49.75 Million | $-16.48 Million | -0.331x | -104.43% |
| 2006-12-31 | $42.21 Million | $-6.84 Million | -0.162x | +60.09% |
| 2005-12-31 | $11.95 Million | $-4.85 Million | -0.406x | +53.41% |
| 2004-12-31 | $7.04 Million | $-6.14 Million | -0.871x | -- |
About MDxHealth SA ADR
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the… Read more